TY - JOUR
T1 - Performance of the China-CLIF framework in acute-on-chronic liver failure
T2 - a multicohort study across all aetiologies
AU - The CANONIC, PREDICT, ACLARA Study Group, Chinese Group on the Study of Severe Hepatitis B (COSSH)
AU - Luo, Jinjin
AU - Hu, Meiqian
AU - Feng, Tingting
AU - Zhang, Liyuan
AU - Huang, Yan
AU - Huang, Yuxian
AU - Ye, Feng
AU - Li, Jiang
AU - Aguilar, Ferran
AU - Sánchez-Garrido, Cristina
AU - Usón-Raposo, Eva
AU - Zhu, Bing
AU - Zhou, Qian
AU - Liang, Xi
AU - Li, Jiaqi
AU - Li, Peng
AU - Xin, Jiaojiao
AU - Shi, Dongyan
AU - Zheng, Jianming
AU - Zhang, Huafen
AU - Wang, Baoju
AU - Qiang, Wei
AU - Yao, Heng
AU - Zhou, Xingping
AU - Chen, Jiaxian
AU - Hu, Wen
AU - Li, Bingqi
AU - Ma, Shiwen
AU - Wu, Xiao
AU - Li, Xiao
AU - Kong, Yuheng
AU - Sun, Feiyang
AU - Chen, Xi
AU - Wu, Tianzhou
AU - Yang, Lingling
AU - Sun, Suwan
AU - Guo, Beibei
AU - He, Lulu
AU - Chen, Jinjun
AU - Xin, Shaojie
AU - Li, Xue
AU - Chen, Huazhong
AU - Angeli, Paolo
AU - Jalan, Rajiv
AU - Lin, Bingliang
AU - Chen, Yu
AU - You, Shaoli
AU - Chen, Xin
AU - Farias, Alberto Queiroz
AU - Trebicka, Jonel
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2026.
PY - 2026/1/1
Y1 - 2026/1/1
N2 - Background Acute-on-chronic liver failure (ACLF) of various aetiologies is a complex syndrome with high short-term mortality and significant global burden. Objective To explore easily applicable diagnostic criteria and an accurate prognostic score for ACLF. Design Clinical data from 5288 patients (after exclusions from 7388 screened) with acute deterioration of chronic liver disease across various aetiologies were used to evaluate the performance of European Chronic Liver Failure (CLIF) and Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria. Three non-Asian cohorts were performed to validate the results. Results CLIF criteria categorised 844 patients as ACLF (28-day/90-day liver transplantation (LT)-free mortality: 40.7%/57.0%; 321 with non-hepatitis B virus (HBV) aetiology, 523 with HBV aetiology), while COSSH criteria categorised 2038 patients as ACLF (mortality: 27.3%/41.0%; 602 with non-HBV aetiology, 1436 with HBV aetiology). COSSH criteria identified 22.6% (1194/5288) more patients (mortality: 19.1%/31.4%) compared with CLIF criteria, including 14.2% non-HBV patients (mortality: 15.9%/33.3%). COSSH criteria produced a more reasonable epidemiological pyramid-like distribution across severity grades (grades 1–3: 63.4%/27.5%/9.1% vs CLIF’s grades 1–3: 25.8%/56.3%/17.9%). COSSH-ACLF II score showed the highest predictive values for 28-day/90-day LT-free mortality in both cirrhotic and all ACLF patients with various aetiologies, outperforming the CLIF-C ACLF and other scores. The comparable performance of China-CLIFs (renamed from COSSH-ACLFs) was validated in three non-Asian cohorts. Conclusions This study evaluated the broader applicability of the China-CLIF framework across diverse aetiologies and varying severity levels of ACLF. These findings may provide a valuable foundation for harmonising ACLF diagnostic and prognostic system.
AB - Background Acute-on-chronic liver failure (ACLF) of various aetiologies is a complex syndrome with high short-term mortality and significant global burden. Objective To explore easily applicable diagnostic criteria and an accurate prognostic score for ACLF. Design Clinical data from 5288 patients (after exclusions from 7388 screened) with acute deterioration of chronic liver disease across various aetiologies were used to evaluate the performance of European Chronic Liver Failure (CLIF) and Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria. Three non-Asian cohorts were performed to validate the results. Results CLIF criteria categorised 844 patients as ACLF (28-day/90-day liver transplantation (LT)-free mortality: 40.7%/57.0%; 321 with non-hepatitis B virus (HBV) aetiology, 523 with HBV aetiology), while COSSH criteria categorised 2038 patients as ACLF (mortality: 27.3%/41.0%; 602 with non-HBV aetiology, 1436 with HBV aetiology). COSSH criteria identified 22.6% (1194/5288) more patients (mortality: 19.1%/31.4%) compared with CLIF criteria, including 14.2% non-HBV patients (mortality: 15.9%/33.3%). COSSH criteria produced a more reasonable epidemiological pyramid-like distribution across severity grades (grades 1–3: 63.4%/27.5%/9.1% vs CLIF’s grades 1–3: 25.8%/56.3%/17.9%). COSSH-ACLF II score showed the highest predictive values for 28-day/90-day LT-free mortality in both cirrhotic and all ACLF patients with various aetiologies, outperforming the CLIF-C ACLF and other scores. The comparable performance of China-CLIFs (renamed from COSSH-ACLFs) was validated in three non-Asian cohorts. Conclusions This study evaluated the broader applicability of the China-CLIF framework across diverse aetiologies and varying severity levels of ACLF. These findings may provide a valuable foundation for harmonising ACLF diagnostic and prognostic system.
KW - HEPATITIS B
KW - LIVER CIRRHOSIS
KW - LIVER FAILURE
UR - https://www.scopus.com/pages/publications/105011750619
U2 - 10.1136/gutjnl-2025-335651
DO - 10.1136/gutjnl-2025-335651
M3 - 文章
C2 - 40713188
AN - SCOPUS:105011750619
SN - 0017-5749
VL - 75
SP - 131
EP - 146
JO - Gut
JF - Gut
IS - 1
ER -